Therma Bright Inc. announced that an initial phase of the Brazilian study of the AcuVidTM saliva-based rapid antigen test has been completed. Therma Bright and its R&D team are now initiating an additional second phase study to optimize AcuVidTM, in collaboration with Safetest Diagnósticos and University of Minas Gerais, to substantiate AcuVidTM test's ability to detect known variants that are currently circulating worldwide. All viruses - including SARS-CoV-2, the virus that causes COVID-19 - evolve over time. When a virus replicates or makes copies of itself, it sometimes changes, which is normal for a virus. These changes are called "mutations". A virus with one or more new mutations is referred to as a "variant" of the original virus. Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.